touchCLINICAL PERSPECTIVES for touchONCOLOGY and touchRESPIRATORY

Module 1: Beyond EGFR: Addressing actionable drug resistance mechanisms

In this module, Professors Jänne and Girard explore the challenges of resistance to EGFR-targeted therapies in non-small cell lung cancer. They discuss how mechanisms such as MET and HER2 amplification drive resistance to first-line osimertinib, review emerging targeted strategies to overcome these barriers, and highlight the importance of biomarker testing and managing treatment side effects when shaping second-line options for patients.

Course director

Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA

The clinical expert

Prof. Nicholas Girard, Institut Curie, Paris, France

Module 2: Bridging resistance gaps post–EGFR-TKI: Expanding NSCLC treatment beyond actionable targets

In this module, Professor Pasi Jänne and Dr. Helena Yu discuss the evolving management of EGFR-mutant NSCLC after EGFR-TKI progression. They address challenges of unexplained resistance, review combination and ADC treatment approaches, and highlight key factors such as patient selection, safety and emerging biomarkers

Course director

Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA

The clinical expert

Dr Helena Yu, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Module 3: Targeting resistance in EGFR-mutant NSCLC: The role of biomarkers

In this module, Professor Pasi Jänne and Professor Paul Hofman explore how precision medicine and molecular resistance mechanisms are shaping testing strategies. They discuss the role of biomarkers, evolving guideline recommendations and how clinicians can adapt testing approaches to align with new targeted therapies.

Course director

Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA

The clinical expert

Prof. Paul Hofman, University Côte d’Azur, Nice, France.

This touchPODCAST is for HCPs only.

This activity is funded by an educational grant from AstraZeneca Ltd.

This medical education is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

For further information visit our website:

https://touchoncologyime.org/egfr-tki-resistance-strategies-nsclc/

https://touchrespiratoryime.org/egfr-tki-resistance-strategies-nsclc/